Table 2 Summary of findings
Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | Number of participants (studies) | Certainty of the evidence (GRADE) | |
|---|---|---|---|---|---|
Risk with mannitol | Risk with HS | ||||
All-cause mortality | 382 per 1000 | 313 per 1000 (187 to 523) | RR 0.82 (0.49 to 1.37) | 105 (3 studies) | Very low |
90-days mortality | 500 per 1000 | 270 per 1000 (115 to 635) | RR 0.54 (0.23 to 1.27) | 58 (2 studies) | Very low |
180-days mortality | 356 per 1000 | 292 per 1000(160 to 540) | RR 0.82 (0.45 to 1.52) | 85 (2 studies) | Very low |
Good neurological outcome | 709 per 1000 | 752 per 1000 (546 to 1000) | RR 1.06 (0.77 to 1.47) | 105 (3 studies) | Very low |
ICP | - | MD 1.9 lower (6.9 lower to 3.1 higher) | - | 58 (2 studies) | Very low |
Serum sodium levels | - | MD 2.6 higher (2.76 lower to 7.97 higher) | - | 105 (3 studies) | Very low |